FR 17027, a new orally absorbed cephalosporin ester, inhibited group A and B streptococci and Streptococcus pneumoniae at S0.1 ,ug/ml, which is similar to the inhibition concentration of amoxicillin and cefaclor, and was more active than cephalexin. It was less active (MIC, 25 ,ug/ml) against staphylococci than was cephalexin, and it did pot inhibit Streptococcus foecalis or Listeria monocytogenes. FR 17027 inhibited I8-lactamase-producing isolates of Neisseria gonorrhoeae, Haemophilus influenzae, and Branhamella patarrhalis at <0.1 ,ug/ml apd was more active than cefaclor or cephalexin against these bacteria. FR 17027 inhibited Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Klebsiella oxytoca, Providencia stuartii, Providencia rettgeri, and Citrobacter diversus at <1 ,ug/ml, including isolates resistant to amoxicillin, cephalexin, and cefaclor, but it was less 'active than ceftizoxime. Some strains of Enterobacter cloacae, Enterobacter agglomerans, Citrobacterfreundii, and Enterobacter aerogenes were resistant (MIC, >25 ,ggml). FR 17027 did not inhibit Pseudomonas aeruginQsa, other Pseudomonas species, Acinetobacter species, or Bacteroides species. Activity was minimally affectWd by growth conditions. FR 17027 was not hydroly4pd by the common ,-lactamases present in many of the pathogens causing respiratory and urinary tract infections in outpatients.
of illness in some children. FR 17P27 (Fig. 1 ) is a new cephalosporin ester which has stability against ,-lactamases and antibacterial activity similar to that of the third generation cephalosporins. FR 17027 is an aminothiazolyl cephalosporin with an ethyl moiety at position three of the dihydrothiazine ring and a carboxyl group affixed to the iminomethoxy portion of the acyl side chain. In studies in our laboratory (D. Brittain, T. Hirose, B. Scully, and H. C. Neu, manuscript in preparation), we have shown that serum levels of 4 ,ug/ml can be achieved after a 400-mg oral dose. We wished to compare the activity of this new cephalosporin with other oral and parenteral antibiotics against a variety of bacteria for which an oral cephalosporin could be used as initial or follow-up therapy.
MATE;RIALS AND METHODS
FR 17027 was a gift from Fujisawa SmithKline Corp. All of the other antibiotics were obtained from their respective manufacturers. Fresh dilutions of compounds were prepared daily in either sterile rpedium or distilled water. The majority of the isolates panme from patients seen at The Presbyterian Hospital, New York, N.Y. Some isolates were gifts sent to our laboratory because of the presence of 1-lactamases, which were characterized by standard methods (2) .
Antimicrobial activity was measured by an agar dilution method with Mueller-Hinton agar unless specified other-* Corresponding author.
wise. A final inoculum of 105 CFU, prepared by dilution of a fresh overnight broth culture, was applied to agar with a replicating spot device. Broth dilutions were performed with a final inoculum of 105 CFU in tubes with a 1-ml volume.
Plates or tubes were incubated at 35°C for 18 h. The MIC was defined as the lowest concentration of antibiotic that inhibited development of visible growth on agar or in broth.
MBC was determined by subculture of 0.1 ml of broth in tubes without visible growth and was defined as the concentration which produced .99.9% reduction in CFU after 24 h of incubation at 35°C. The susceptibility of streptococci was determined by using Mueller-Hinton agar supplemented with 5% human blood. The susceptibility of Neisseria and Haemophilus species was determined on lysed human bloodMueller-Hinton agar in the presence of 5% CO2. Anaerobic bacterial susceptibility was determined by using brucella agar supplemented with sheep blood and vitamin K. Incubation of anaerobic bacterial cultures was for 48 h in GasPak jars (BBL Microbiology Systems, Cockeysville, Md.).
Susceptibility tests to the various drugs were performed with permeability mutants provided by Clark (1) and Richmond et al. (5) . Strains DC2, DC3, and DC13 do not have a barrier to the entry of 3-lactam antibiotics.
The bactericidal activity of FR 17027 was determined by incubating clinical isolates of Escherichia coli, which contained the TEM-1 ,-lactamase, and Klebsiella pneumoniae, which contained an SHV-1 f-lactamase. ,B-Lactamases have been identified by jsoelectric focusing (2). Growth was followed by the change in optical density. Sidearm flasks were used with incubation at 37°C in a gyratory shaker.
The presence of j-lactamase in isolates was determined by the nitrocefin assay. ,-Lactamases used for the analysis of the stability of the compounds were either purified enzymes or partially purified enzymes as previously described (2).
Stability to 1-lactamase was determined by a spectrophotometric assay by using the change in absorbance at the absorption maximum of each substrate. Inhibition assays, with nitrocefin as the substrate, were performed with 10-4 M \C-COOHr The activity of FR 17027, cephalexin, cefaclor, and amoxicillin was tested against E. coli isolates which were shown to contain TEM-1 and TEM-2 P-lactamases, as determined by isoelectric focusing. Only FR 17027 had an MIC of <0. 4 ,ug/ml, whereas the other agents had MICs of .25 ,ug/ml.
The ,-lactamase stability of FR 17027, cephalexin, cephradine, and cefaclor is shown in Corynebacterium JK species These observations indicate that FR 17027 may prove to be a useful agent for treating selected upper respiratory tract infections in children and adults, and it may also be effective in some urinary tract infections. Current studies in our laboratory indicate that concentrations well above MBCs for most of the common organisms producing respiratory and urinary infections can be obtained with 200-and 400-mg doses.
